Psoriasis vulgaris is a chronic disease in which psoriatic plaques may appear on the knees, elbows, scalp and trunk. Evidence suggests the role of neurogenic inflammation in the pathogenesis of psoriasis. Botulinum toxin has been shown to have an effect on inhibiting neurogenic inflammation. Recently, it was reported that patients who suffered from dystonia and had concomitant psoriasis, when treated with botulinum toxin for dystonia noted a dramatic improvement of their psoriatic lesions. This pilot study will determine the safety and efficacy of botulinum toxin in the management of psoriasis vulgaris.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
8
35 to 100 units injected around a skin lesion (plaque) one time.
Univerisity of Minnesota
Minneapolis, Minnesota, United States
psoriasis scoring scale
Time frame: baseline and 3months
3mm skin biopsy.
Time frame: baseline and at 3 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.